Gallery
Picture 1
Abbvie stock price forecast analysts stress AbbVie’s strong R&D
New with box
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Analysts stress AbbVie’s strong R&D leadership, essential for high-confidence price forecasts. The stock’s beta under 0.7 also makes it attractive in portfolio risk-adjusted return modeling. AbbVie Inc. (NYSE: ABBV ) ranks among the stocks with low beta that can beat market volatility . On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had reached a settlement that would allow generic Rinvoq to be introduced in April 2037, over four years later than Leerink had previously predicted. Exclusive news, data and analytics for financial market professionals For traders, AbbVie presents a classic “dividend-growth with capital appreciation” play. The stock’s relative strength index (RSI) suggests it remains in healthy territory, with forecast models pointing to steady demand from institutional allocators through early